Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.10% | -39.36% | -40.59% | -34.33% | -30.88% |
| Total Depreciation and Amortization | 153.64% | 102.42% | 61.50% | 25.63% | 11.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.46% | 67.47% | 72.92% | 60.43% | 34.21% |
| Change in Net Operating Assets | 44.64% | 858.98% | 492.09% | 167.96% | -56.78% |
| Cash from Operations | -35.88% | -22.58% | -11.36% | -25.33% | -44.36% |
| Capital Expenditure | 18.00% | 6.88% | -456.00% | -278.80% | -183.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -191.72% | -61.01% | -361.61% | -202.60% | -13.58% |
| Cash from Investing | -186.82% | -57.42% | -369.59% | -204.08% | -15.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 157.45% | 37.45% | 5,453.26% | 538.96% | 217.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -117.47% | 16.19% | -12,296.43% | -396.84% | -193.05% |
| Cash from Financing | 159.79% | 40.78% | 5,306.21% | 548.09% | 218.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 843.34% | 55.94% | 1,296.94% | 442.56% | 113.29% |
